Biotech Investing Moleculin Enters Agreement with BSP Pharmaceuticals for its Leukemia Drug Candidate
Pharmaceutical Investing Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Pharmaceutical Investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
Biotech Investing Bio-Path Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine
Pharmaceutical Investing Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
Pharmaceutical Investing Novartis drug Tasigna approved by FDA to treat children with rare form of leukemia
Pharmaceutical Investing MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
Pharmaceutical Investing Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B
Pharmaceutical Investing Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M
Pharmaceutical Investing Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M